The Fund Exited Natera (NTRA) on Valuation Concerns Despite Strong Fundamentals
Baron Capital's fund gained 3.3% in Q3 2026, outperforming benchmarks. It sold Natera (NTRA) due to valuation concerns, despite strong fundamentals. NTRA closed at $311.98 on Nov 10, 2026, with a 36.18% YTD gain and $45.23B market cap. The fund remains optimistic about AI and Space Economy.
How this was made

The 30-second read
Why it matters
The disclosed sale of Natera signals valuation concerns and may influence other fund managers and retail investors.
Market read
Fund exit provides a fresh data point for NTRA valuation and may affect short‑term price dynamics.
What to watch
Potential upcoming product launches or reimbursement approvals could offset valuation concerns.
Background
Baron Capital’s Q3 2026 investor letter disclosed its top holdings and recent trades.
Ticker impact
Baron Global Opportunity Fund sold its stake in Natera, citing extreme valuation.
likely downward pressure as the market prices in the valuation concerns.
A sizable fund disclosed a sale, indicating reduced confidence and may prompt other investors to follow.
Market effects
Health Care diagnostics may see broader scrutiny on valuation multiples.
US biotech sector could face modest sell‑off pressure.
Limited to investors tracking fund flows and biotech valuations.
Counterpoint
The fund may have exited prematurely; long‑term growth prospects remain strong.
Key entities
- FundBaron Global Opportunity Fund
Investment fund managed by Baron Capital.
- CompanyNatera, Inc.
Diagnostics company specializing in cell‑free DNA testing.



